ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY. (12th June 2019)

• Record Type: Journal Article
• Authors: Gregory, G.; Walker, P.; Mahadevan, D.; Wang, D.; Chang, J.; Hernandez‐Ilizaliturri, F.; Klein, A.; Rybka, W.; Wagner‐Johnston, N.; Escobar, C.; Pagel, J.M.; Mohrbacher, A.; Opat, S.; Shortt, J.; Ma, H.; Gwo, J.; Farooqui, M.; Quach, H.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 328
• Page End: 329
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.140_2630
• Languages: English
• ISSNs: 0278-0232